semaglutide pharmaceutical company Explainer: What's behind the scramble for semaglutide? Aspen Pharmacare wins Canada approval

The Medicare GLP-1 Bridge, running July 1, 2026 through December 31, 2027, is likely to end or be significantly narrowed at expiration unless CMS secures broader insurer participation, since insurers already declined to sign onto a permanent 2027 Part D balance model and the program was extended from an original 6-month plan only because of that shortfall

300, Suite 103, Watkinsville, GA 30677, USA Contact: 866 753 0747 5

For example, a 0.5 mg daily dose becomes 0.25 mg in the morning and 0.25 mg in the evening

7 , e2322 (2016)

Regulatory Approval Status by Jurisdiction (2026) As of June 2026, retatrutide (LY3437943) has not received regulatory approval as a therapeutic in any jurisdiction

I call this the Rule of Nigella Lawson: You can gauge someones baseline relationship to pleasure by how they approach a meal